Oculus Innovative Sciences, Inc., together with its subsidiaries, engages in the development, manufacture, and marketing of various products to prevent and treat infection in acute and chronic wounds. The company's platform technology includes Microcyn, a proprietary oxychlorine small molecule formulation designed to treat a range of organisms that cause disease or pathogens, including viruses, fungi, spores, and antibiotic resistant strains of bacteria, such as Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococcus in wounds. It offers Microcyn under its 510(k) clearances in the United States primarily through Website, a national distributor, and regional distributors. The company was incorporated in 1999 as Micromed Laboratories, Inc. and changed its name to Oculus Innovative Sciences, Inc. in 2001. Oculus Innovative is based in Petaluma, California.